Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study of 1st and 2nd Line Vectibix® Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates

NCT02322736 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02322736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02322736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study of 1st and 2nd Line Vectibix® Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
November 21, 2014
Completion date
August 3, 2018
Enrollment
218 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer